As Biotechnology businesses, Akari Therapeutics Plc (NASDAQ:AKTX) and CRISPR Therapeutics AG (NASDAQ:CRSP), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akari Therapeutics Plc||2||0.00||10.35M||-0.78||0.00|
|CRISPR Therapeutics AG||56||0.00||34.37M||-0.46||0.00|
In table 1 we can see Akari Therapeutics Plc and CRISPR Therapeutics AG’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the return on equity, net margins and return on assets of Akari Therapeutics Plc and CRISPR Therapeutics AG.
|Net Margins||Return on Equity||Return on Assets|
|Akari Therapeutics Plc||557,050,592.03%||-716.4%||-158.5%|
|CRISPR Therapeutics AG||61,265,597.15%||-2.6%||-2%|
The Current Ratio and Quick Ratio of Akari Therapeutics Plc are 1.7 and 1.7 respectively. Its competitor CRISPR Therapeutics AG’s Current Ratio is 8.3 and its Quick Ratio is 8.3. CRISPR Therapeutics AG can pay off short and long-term obligations better than Akari Therapeutics Plc.
The following table delivered below contains the ratings and recommendations for Akari Therapeutics Plc and CRISPR Therapeutics AG.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Akari Therapeutics Plc||0||0||0||0.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
On the other hand, CRISPR Therapeutics AG’s potential downside is -1.41% and its consensus price target is $66.5.
Institutional and Insider Ownership
Roughly 3.4% of Akari Therapeutics Plc shares are held by institutional investors while 46.8% of CRISPR Therapeutics AG are owned by institutional investors. Insiders held roughly 57.08% of Akari Therapeutics Plc’s shares. Competitively, 0.4% are CRISPR Therapeutics AG’s share held by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Akari Therapeutics Plc||-3.88%||10.61%||3.66%||-5.71%||10%||26.11%|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year Akari Therapeutics Plc has weaker performance than CRISPR Therapeutics AG
CRISPR Therapeutics AG beats on 8 of the 10 factors Akari Therapeutics Plc.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barrÃ© syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.